Changes in CoQ10/Lipids Ratio, Oxidative Stress, and Coenzyme Q10 during First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma (mUC)

被引:0
|
作者
Palacka, Patrik [1 ,2 ]
Kucharska, Jarmila [3 ]
Obertova, Jana [1 ,2 ]
Rejlekova, Katarina [1 ,2 ]
Slopovsky, Jan [1 ,2 ]
Mego, Michal [1 ,2 ]
Svetlovska, Daniela [1 ,2 ]
Kollarik, Boris [4 ]
Mardiak, Jozef [1 ,2 ]
Gvozdjakova, Anna [3 ]
机构
[1] Comenius Univ, Fac Med, Dept Oncol 2, Bratislava 83310, Slovakia
[2] Natl Canc Inst, Bratislava 83310, Slovakia
[3] Comenius Univ, Fac Med, Pharmacobiochem Lab, Dept Internal Med 3, Bratislava 81372, Slovakia
[4] Univ Hosp Bratislava, Dept Urol, Bratislava 85107, Slovakia
关键词
metastatic urothelial carcinoma; cisplatin; coenzyme Q(10) /lipids ratio; alpha-tocopherol; thiobarbituric acid-reactive substances; BLADDER-CANCER; PLASMA; SURVIVAL; LDL;
D O I
10.3390/ijms232113123
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oxidative stress plays an important role in cancer pathogenesis, and thiobarbituric acid-reactive substance level (TBARS)-a parameter of lipid peroxidation-has prognostic significance in chemotherapy-naive patients with metastatic urothelial carcinoma (mUC). However, the effect of cisplatin (CDDP)-based chemotherapy on oxidative stress, coenzyme Q(10), and antioxidants remains unknown. The objective of this prospective study was to determine possible changes in the CoQ(10) (coenzyme Q(10))/lipids ratio, antioxidants (alpha-tocopherol, gamma-tocopherol, beta-carotene, CoQ(10)), total antioxidant status (TAS), and TBARS in plasma at baseline and during first-line chemotherapy based on CDDP in mUC subjects. In this prospective study, 63 consecutive patients were enrolled. The median age was 66 years (range 39-84), performance status according to the Eastern Cooperative Oncology Group (ECOG) was 2 in 7 subjects (11.1%), and visceral metastases were present in 31 (49.2%) patients. Plasma antioxidants were determined by HPLC and TAS and TBARS spectrophotometrically. After two courses of chemotherapy, we recorded significant enhancements compared to baseline for total cholesterol (p < 0.0216), very low-density lipoprotein (VLDL) cholesterol (p < 0.002), triacylglycerols (p < 0.0083), alpha-tocopherol (p < 0.0044), and coenzyme Q(10)-TOTAL (p < 0.0001). Ratios of CoQ(10)/total cholesterol, CoQ(10)/HDL-cholesterol, and CoQ(10)/LDL-cholesterol increased during chemotherapy vs. baseline (p < 0.0048, p < 0.0101, p < 0.0032, respectively), while plasma TBARS declined (p < 0.0004). The stimulation of antioxidants could be part of the defense mechanism during CDDP treatment. The increased index of CoQ(10-TOTAL)/lipids could reflect the effect of CDDP protecting lipoproteins from peroxidation.
引用
收藏
页数:17
相关论文
共 18 条
  • [1] Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
    Hsieh, Meng-Che
    Huang, Cheng-Hua
    Chiang, Po-Hui
    Chen, Yen-Yang
    Tang, Yeh
    Su, Yu-Li
    JOURNAL OF CANCER, 2016, 7 (10): : 1347 - 1352
  • [2] Effect of Coenzyme Q10 on Biomarkers of Oxidative Stress and Cardiac Function in Hemodialysis Patients: The CoQ10 Biomarker Trial
    Rivera, Matthew B.
    Yeung, Catherine K.
    Robinson-Cohen, Cassianne
    Phillips, Brian R.
    Ruzinski, John
    Rock, Denise
    Linke, Lori
    Shen, Danny D.
    Ikizler, T. Alp
    Himmelfarb, Jonathan
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2017, 69 (03) : 389 - 399
  • [3] Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy
    Galsky, Matthew D.
    Moshier, Erin
    Krege, Susan
    Lin, Chia-Chi
    Hahn, Noah
    Ecke, Thorsten
    Sonpavde, Guru
    Pond, Gregory
    Godbold, James
    Oh, William K.
    Bamias, Aristotle
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 48.e1 - 48.e8
  • [4] Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma
    Fina, Emanuela
    Necchi, Andrea
    Giannatempo, Patrizia
    Colecchia, Maurizio
    Raggi, Daniele
    Daidone, Maria Grazia
    Cappelletti, Vera
    BLADDER CANCER, 2016, 2 (04) : 395 - 403
  • [5] Early switching to pembrolizumab (Pe) during first-line platinum-based chemotherapy (PCT) in patients (pts) with metastatic urothelial carcinoma (mUC).
    Endo, Yuki
    Kimura, Go
    Akatsuka, Jun
    Takeda, Hayato
    Yanagi, Masato
    Mikami, Hikaru
    Hasegawa, Hiroya
    Taniuchi, Mami
    Katsu, Akifumi
    Funato, Ryota
    Toyama, Yuka
    Kondo, Yukihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [6] EFFICACY OF CISPLATIN-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT IN ASIAN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA RESULTS OF AN EXPLORATORY SUBGROUP ANALYSIS OF A POOL ANALYSIS OF PHASE II/III TRIALS
    Lin, C. -C.
    Galsky, M. D.
    Krege, S.
    Hahn, N. M.
    Ecke, T.
    Sonpavde, G.
    Oh, K.
    Bamias, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 96 - 97
  • [7] IMPACT OF PLATINUM AGENT [CISPLATIN (CIS) OR CARBOPLATIN (CA)] IN FIRST-LINE CHEMOTHERAPY (CT) ON OVERALL SURVIVAL IN METASTATIC UROTHELIAL CARCINOMA (MUC) PATIENTS (PTS): A RETROSPECTIVE STUDY
    Auvray, M.
    Vano, Y.
    Combe, P.
    Elaidi, R.
    Auclin, E.
    Takouchop, C.
    Medioni, J.
    Scotte, F.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2014, 25
  • [8] Relationship between 6-and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy
    Galsky, Matthew D.
    Krege, Susan
    Lin, Chia-Chi
    Hahn, Noah
    Ecke, Thorsten
    Moshier, Erin
    Sonpavde, Guru
    Godbold, James
    Oh, William K.
    Bamias, Aristotle
    CANCER, 2013, 119 (16) : 3020 - 3026
  • [9] The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT).
    Necchi, Andrea
    Sonpavde, Guru
    Lo Vullo, Salvatore
    Bamias, Aristotelis
    Crabb, Simon J.
    Harshman, Lauren Christine
    Bellmunt, Joaquim
    De Giorgi, Ugo
    Sternberg, Cora N.
    Ladoire, Sylvain
    Wong, Yu-Ning
    Yu, Evan Y.
    Chowdhury, Simon
    Niegisch, Guenter
    Srinivas, Sandy
    Vaishampayan, Ulka N.
    Pal, Sumanta K.
    Rosenberg, Jonathan E.
    Galsky, Matt D.
    Mariani, Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report
    Mao, Shiyu
    Zhang, Junfeng
    Guo, Yadong
    Zhang, Ziwei
    Wu, Yuan
    Zhang, Wentao
    Wang, Longsheng
    Geng, Jiang
    Yan, Yang
    Yao, Xudong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 291 - 300